Please ensure Javascript is enabled for purposes of website accessibility

Why Clovis Oncology Stock Is Popping Today

By George Budwell - Updated Feb 5, 2020 at 1:12PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

It could be a top buyout target soon.

What happened

Shares of the small-cap cancer specialist Clovis Oncology (CLVS 2.34%) were up 12%, on average volume, as of 12:05 p.m. EST Wednesday. The biotech's stock appears to be getting a boost from the rampant speculation about the upcoming buyout bonanza expected to take place across the industry. Fellow cancer drugmakers Atara Biotherapeutics, Exelixis, and Puma Biotechnology are all on the move as well today.

So what

Clovis has long been rumored to be a top buyout target, thanks to the sizable commercial potential of its PARP inhibitor known as Rubraca. At present, Rubraca is approved as a treatment for advanced ovarian cancer, where its sales have seriously lagged behind competitors from AstraZeneca and GlaxoSmithKline.

A blood sample positive for the prostate specific antigen.

Image source: Getty Images.

By May 15 of this year, however, the Food and Drug Administration is widely expected to expand the drug's label to include adult men with recurrent, metastatic BRCA1/2 mutation-positive, castration-resistant prostate cancer. Taken together, these two indications have the potential to push the drug's sales over $700 million per year by 2025. Given that Clovis' market cap is only $715 million at the moment, it may prove to be too good a bargain for potential suitors to pass up. 

Now what

Where is this buyout speculation emanating from? First and foremost, it's no secret that Gilead Sciences is aggressively looking for new sources of growth right now. In addition, Pfizer, GlaxoSmithKline, and Merck are all expected to be big players on the mergers and acquisitions scene this year. So there should be plenty of suitors for undervalued cancer companies like Clovis with products already on the market.  

 

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Clovis Oncology, Inc. Stock Quote
Clovis Oncology, Inc.
CLVS
$0.69 (2.34%) $0.02

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
356%
 
S&P 500 Returns
124%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/28/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.